Viral-vectored respiratory mucosal vaccine strategies.

Curr Opin Immunol

McMaster Immunology Research Centre and Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada. Electronic address:

Published: October 2023

Increasing global concerns of pandemic respiratory viruses highlight the importance of developing optimal vaccination strategies that encompass vaccine platform, delivery route, and regimens. The decades-long effort to develop vaccines to combat respiratory infections such as influenza, respiratory syncytial virus, and tuberculosis has met with challenges, including the inability of systemically administered vaccines to induce respiratory mucosal (RM) immunity. In this regard, ample preclinical and available clinical studies have demonstrated the superiority of RM vaccination to induce RM immunity over parenteral route of vaccination. A great stride has been made in developing vaccines for RM delivery against respiratory pathogens, including M. tuberculosis and SARS-CoV-2. In particular, inhaled aerosol delivery of adenoviral-vectored vaccines has shown significant promise.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2023.102370DOI Listing

Publication Analysis

Top Keywords

respiratory mucosal
8
respiratory
5
viral-vectored respiratory
4
mucosal vaccine
4
vaccine strategies
4
strategies increasing
4
increasing global
4
global concerns
4
concerns pandemic
4
pandemic respiratory
4

Similar Publications

Background: Beedi rolling is a labor-intensive occupation that can cause a variety of health problems due to prolonged exposure to tobacco dust. This cross-sectional study aimed to assess morbidity, hematological profile, and DNA damage among beedi rollers in Karnataka.

Methods: A total of 153 participants, including 85 beedi and 65 non-beedi rollers, were enrolled in the study.

View Article and Find Full Text PDF

Background: The microbiome regulates the respiratory epithelium's immunomodulatory functions. To explore how the microbiome's biodiversity affects microbe-epithelial interactions, we screened 58 phylogenetically diverse microbes for their transcriptomic effect on human primary bronchial air-liquid interface (ALI) cell cultures.

Results: We found distinct species- and strain-level differences in host innate immunity and epithelial barrier response.

View Article and Find Full Text PDF

Coeliac disease: complications and comorbidities.

Nat Rev Gastroenterol Hepatol

January 2025

Takeda Pharmaceuticals, Cambridge, MA, USA.

Coeliac disease is an autoimmune disease characterized by small intestinal villus atrophy and inflammation upon exposure to gluten. It has a global prevalence of approximately 1%. Although the gluten-free diet can be an effective treatment, this diet is burdensome with practical difficulties and frequent inadvertent gluten exposure.

View Article and Find Full Text PDF

Robust mucosal SARS-CoV-2-specific T cells effectively combat COVID-19 and establish polyfunctional resident memory in patient lungs.

Nat Immunol

January 2025

State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Mucosal antigen-specific T cells are pivotal for pathogen clearance and immune modulation in respiratory infections. Dysregulated T cell responses exacerbate coronavirus disease 2019 severity, marked by cytokine storms and respiratory failure. Despite extensive description in peripheral blood, the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells in the lungs remain elusive.

View Article and Find Full Text PDF

Correlates of Protection Against Symptomatic COVID-19: The CORSER 5 Case-Control Study.

Open Forum Infect Dis

January 2025

Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.

Background: Establishing correlates of protection often requires large cohorts. A rapid and adaptable case-control study design can be used to identify antibody correlates of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in serum and saliva.

Methods: We designed a case-control study to compare antibody levels between cases of SARS-CoV-2 infection within 5 days of symptom onset and uninfected controls.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!